A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells

Cancer Research

Volumn 68, Issue 18, 2008, Pages 7253-7257

  Winner, Millicent ^a   Meier, Jason ^a   Zierow, Swen ^d   Rendon, Beatriz E ^a   Crichlow, Gregg V ^d   Riggs, Randall ^c   Bucala, Richard ^d   Leng, Lin ^d   Smith, Ned ^b   Lolis, Elias ^d   Trent, John O ^a   Mitchell, Robert A ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

^c Advanced Cancer Therapeutics   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID METHYL ESTER; 4 IODO 6 PHENYLPYRIMIDINE; 6 PHENYLPYRIMIDINE; ANTINEOPLASTIC AGENT; CYTOKINE RECEPTOR ANTAGONIST; ISO 1; MACROPHAGE MIGRATION INHIBITION FACTOR; SUICIDE SUBSTRATE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER INHIBITION; CATALYSIS; CELL MIGRATION; CELL MOTILITY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; LUNG ADENOCARCINOMA; LUNG CANCER; MASS SPECTROMETRY; PARACRINE SIGNALING; PRIORITY JOURNAL; VIRTUAL REALITY;

ADENOCARCINOMA; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; ISOXAZOLES; LUNG NEOPLASMS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MODELS, MOLECULAR; PYRIMIDINES;

EID: 54749101549     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6227     Document Type: Article

References (20)

1. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76.
2. Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006;25:595-606.
3. Swant JD, Rendon BE, Symons M, Mitchell RA. Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J Biol Chem 2005;280:23066-72.
4. Rendon BE, Roger T, Teneng I, et al. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 2007;282:29910-8.
5. Singleton PA, Dudek SM, Ma SF, Garcia JG. Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem 2006;281:34381-93.
6. Rosengren E, Bucala R, Aman P, et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 1996;2:143-9.
7. Swope M, Sun HW, Blake PR, Lolis E. Direct link between cytokine activity anda catalytic site for macrophage migration inhibitory factor. EMBO J 1998;17:3534-41.
8. Hermanowski-Vosatka A, Mundt SS, Ayala JM, et al. Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis andr andom migration. Biochemistry 1999;38:12841-9.
9. Lubetsky JB, Dios A, Han J, et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 2002;277:24976-82.
10. Al Abed Y , Dabideen D, Aljabari B, et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity andin creases survival in severe sepsis. J Biol Chem 2005;280:36541-4.
11. Crichlow GV, Cheng KF, Dabideen D, et al. Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffoldin the active site of macrophage migration inhibitory factor. J Biol Chem 2007;282:23089-95.
12. Dabideen DR, Cheng KF, Aljabari B, Miller EJ, Pavlov VA, Al Abed Y. Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity andsu rvival improving agents in sepsis. J Med Chem 2007;50:1993-7.
13. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006;177:8730-9.
14. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994;33:14144-55.
15. Otwinowski Z, Minor W. Processing of X-ray Diffraction Data Collectedin Oscillation Mode, Methods in Enzymology, Volume 276: Macromolecular Crystallography, part A. 1997. Carter CW, Jr., Sweet RM, editors. Academic Press (New York). 2007. p. 307-326.
16. Storoni LC, McCoy AJ, Read RJ. Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr 2004;60:432-8.
17. Brunger AT, Adams PD, Clore GM, et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998;54:905-21.
18. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Cystallogr 1997;53:240-55.
19. Sun HW, Bernhagen J, Bucala R, Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 1996;93:5191-6.
20. Orita M, Yamamoto S, Katayama N, et al. Coumarin andchromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. J Med Chem 2001;44:540-7.